# Canagliflozin in Patients With Acute Decompansted Heart Failure

> **NCT05364190** · PHASE3 · COMPLETED · sponsor: **October 6 University** · enrollment: 142 (actual)

## Conditions studied

- Chronic Heart Failure
- Acute Heart Failure
- Diabetes Mellitus

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05364190
- **Lead sponsor:** October 6 University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-04
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2024-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364190, "Canagliflozin in Patients With Acute Decompansted Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05364190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*